The top winners and losers on ASCO abstract night: Loxo, Blueprint, Jounce, Merck KGaA and more
Let the jousting begin.
The big abstract drop ahead of ASCO — the annual Olympics of cancer R&D — provided some early, quick snapshots that helped drive stocks up or down, or simply provided a chance to tout some potential in a hotly contested field.
As more and more biopharma money has been invested in the oncology field in recent years, ASCO has been attracting a bigger range of entrants, and abstract night will help determine who comes out on top during the melee ahead. I’ve picked out a few of the most noticeable abstracts, which you can see below.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.